Multitarget FAAH and COX inhibitors

The invention provides novel multitarget inhibitors of FAAH, COX-1 and/or COX-2. The invention concerns also with therapeutical application of the multitarget inhibitors in particular in the prevention and treatment of cancer.

Title of the patent Multitarget FAAH and COX inhibitors and therapeutical uses thereof
Thematic area Pharmaceutical
Ownership Alma Mater Studiorum - Università di Bologna, Fondazione Istituto Italiano di Tecnologia, The Regents of the University of California
Inventors Andrea Cavalli, Rita Scarpelli, Marco De Vivo, Marco Migliore, Daniele Piomelli
Protection Italy, Germany, France, Great Britain, Australia, Canada, USA, Japan
Licensing status Available for licensing agreement
Keywords Anti-inflammatory drugs, multitarget, polypharmacology, FAAH, COX multitarget, inhibitors, cancer
Filed on Aug 06, 2012

Inflammatory pathologies afflict hundreds of millions of people worldwide. Yet the use of current therapies is limited by potentially serious side effects, such as gastric damage, kidney damage and increased risk of stroke.

Therefore, a need still exists for new therapeutically active compounds, which are effective in the treatment of inflammation and related conditions whose administration results in a reduced risk of side effects in humans.

The invention provides novel compounds that simultaneously inhibit the enzymes Fatty Acid Amide Hydrolase (FAAH), Cyclooxygenase-1 (COX-1) and/or Cyclooxygenase-2 (COX-2), and therapeutic uses of such compounds.

The compounds of the invention find application in the medical field, in the treatment of pathological conditions in which simultaneous inhibition of FAAH, COX-1 and/or COX-2 activities is desirable. The combined FAAH and COX-1 and/or COX-2 inhibitors are useful in the treatment of cancer and precancerous conditions and find additional applications in the treatment of inflammatory diseases, pain, eating disorders, anxiety and cardiovascular disorders.